Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer

EJNMMI Reports

Table 4 Results of receiver-operator characteristic curve analyses of bone metastases from patient-based and lesion-based analyses

	AUC	Confidence interval
	AUC	lower limit	upper limit
Patient-based with ALP and PSA (52 BM vs. 100 DC)
SUVmax	0.824	0.742	0.906
SUVpeak	0.801	0.712	0.889
SUVave	0.829	0.748	0.911
ALP	0.660	0.557	0.763
PSA	0.640	0.538	0.742
Patient-based (56 BM vs. 114 DC)
SUVmax	0.808	0.723	0.893
SUVpeak	0.785	0.694	0.875
SUVave	0.813	0.729	0.898
Lesion-based (126 BM vs. 354 DC)
SUVmax	0.926	0.900	0.953
SUVpeak	0.911	0.879	0.943
SUVave	0.924	0.895	0.954

AUC area under curve, BM bone metastases, DC degenerative changes, ALP alkaline phosphatase, PSA prostate specific antigen